Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Jaap J.M. Teunissen"'
Autor:
Dik J. Kwekkeboom, Eric P. Krenning, Gaston J.H. Franssen, Casper H.J. van Eijck, Wouter W. de Herder, Richard A. Feelders, Boen L.R. Kam, Jaap J.M. Teunissen, Wouter A. van der Zwan, Tessa Brabander
Supplement Table 1. A. Characteristics of the 4 patients with acute leukemia in follow-up
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bac13d22837408bf49aa3d1b183f40b
https://doi.org/10.1158/1078-0432.22462970
https://doi.org/10.1158/1078-0432.22462970
Autor:
Dik J. Kwekkeboom, Eric P. Krenning, Gaston J.H. Franssen, Casper H.J. van Eijck, Wouter W. de Herder, Richard A. Feelders, Boen L.R. Kam, Jaap J.M. Teunissen, Wouter A. van der Zwan, Tessa Brabander
Purpose: Bronchial and gastroenteropancreatic neuroendocrine tumors (NET) are slow-growing tumors, which frequently express somatostatin receptors on their cell membranes. These receptors are targets for therapy with Lutetium-177–labeled somatostat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c4612c0e165b6fe528605236248f6c1
https://doi.org/10.1158/1078-0432.c.6525275.v1
https://doi.org/10.1158/1078-0432.c.6525275.v1
Autor:
Dik J. Kwekkeboom, Eric P. Krenning, Gaston J.H. Franssen, Casper H.J. van Eijck, Wouter W. de Herder, Richard A. Feelders, Boen L.R. Kam, Jaap J.M. Teunissen, Wouter A. van der Zwan, Tessa Brabander
Supplement Figure 1. Median overall survival for patients receiving a cumulative dose of {greater than or equal to}100 mCi 177Lu-DOTATATE with a primary NET located in the midgut with and without progression at baseline.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d00c190e0f54b7ce466c4d6e8310c42d
https://doi.org/10.1158/1078-0432.22462967.v1
https://doi.org/10.1158/1078-0432.22462967.v1
Autor:
Boen Liong Kam, Jaap J.M. Teunissen, Johannes Hofland, Tessa Brabander, E. P. Krenning, W. A. van der Zwan, W. W. de Herder, Richard A Feelders
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging, 46(3), 704-717. Springer-Verlag
Therapy with [177Lu-DOTA,Tyr3]octreotate is effective in patients with grade I/II metastasized and/or inoperable bronchial neuroendocrine tumour (NET) or gastroenteropancreatic NET (GEP-NET). In this study, we investigated the efficacy and safety of
Autor:
Johannes Hofland, Wouter W. de Herder, Boen L. R. Kam, Tessa Brabander, Wouter T Zandee, Jaap J.M. Teunissen, Richard A Feelders, Anela Blažević
Publikováno v:
Journal of Clinical Endocrinology and Metabolism, 104(4), 1336-1344. Endocrine Society
Purpose: Peptide receptor radionuclide therapy (PRRT) with the radiolabeled somatostatin analogue [Lutetium-177-DOTA0 -Tyr3 ]octreotate (177Lu-DOTATATE) is widely applied for inoperable metastatic small intestinal and nonfunctioning pancreatic neuroe
Autor:
Anne van Linge, Wouter W. de Herder, Esther Korpershoek, Jaap J.M. Teunissen, Rogier A. Oldenburg, Johanna M. Hendriks, Tessa Brabander, Johannes Hofland, Gaston J H Franssen, Cleo Slagter, Daan A. Smit Duijzentkunst, Huda Abusaris, Wouter T Zandee, R Mick Metselaar, Boen L. R. Kam, Richard A Feelders
Publikováno v:
European Journal of Endocrinology, 181(1), 45-53. Bioscientifica Ltd
Objectives Inoperable or metastatic paragangliomas (PGLs) and malignant pheochromocytomas (PCCs) are rare tumours with limited options for systemic treatment. Aim of this study was to assess the safety and efficacy of the radiolabelled somatostatin a
Autor:
Richard A Feelders, Jaap J.M. Teunissen, Tessa Brabander, Eric P. Krenning, Boen L. R. Kam, Wouter A. van der Zwan, Wouter W. de Herder, Dik J. Kwekkeboom
Publikováno v:
Endocrine-Related Cancer, 24(5), 243-251. Bioscientifica Ltd
Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE) is a treatment with good results in patients with metastatic gastroenteropancreatic neuroendocrine tumours (GEPNETs). However, there are some pitfalls tha
Publikováno v:
Clinical Nuclear Medicine, 42(1), 15-19. Lippincott Williams & Wilkins
Purpose Physiological uptake in the uncinate process or pancreatic head has been described with Ga-labeled PET tracers for somatostatin receptor imaging. In-DTPA-octreotide is the only registered radiopharmaceutical for the imaging of neuroendocrine
Autor:
Eric P. Krenning, Dik J. Kwekkeboom, Wouter A. van der Zwan, Hendrik Bergsma, P. P. M. Kooij, Boen L. R. Kam, Mark Konijnenberg, Jaap J.M. Teunissen, Katya Mauff
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging
Purpose After peptide receptor radionuclide therapy (PRRT), renal toxicity may occur, particular in PRRT with 90Y-labelled somatostatin analogues. Risk factors have been identified for increased probability of developing renal toxicity after PRRT, in
Autor:
Dik J. Kwekkeboom, Casper H.J. van Eijck, Tessa Brabander, Gaston J H Franssen, Jaap J.M. Teunissen, Richard A Feelders, Wouter W. de Herder
Publikováno v:
Best Practice & Research Clinical Endocrinology & Metabolism, 30(1), 103-114. Bailliere Tindall Ltd
In the past decades, the number of neuroendocrine tumours that are detected is increasing. A relative new and promising therapy for patients with metastasised or inoperable disease is peptide receptor radionuclide therapy (PRRT). This therapy involve